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Context. Neuropathic pain (NP) may be an important contributor to the morbidity burden of breast cancer.
Objectives. We aimed to quantify the incidence of NP in the first year after diagnosis of breast cancer and to identify its
main determinants.
Methods. We performed a prospective cohort study including 506 patients with incident breast cancer, recruited at the
Portuguese Institute of Oncology of Porto, and followed for one year; patients with incident NP were additionally evaluated
when this condition was diagnosed and after six months, to identify chronic NP.
Results. During the first year, 156 patients were diagnosed with NP (30.8%, 95% CI 27.0e35.0). Anxiety (relative risk [RR]
1.50; 95% CI 1.06e2.13), arm symptoms (RR 1.44; 95% CI 1.02e2.05), cancer Stage III/IV (RR 2.47; 95% CI 1.66e3.66),
breast-conserving surgery with axillary lymph node dissection (RR 3.13; 95% CI 1.51e6.48), mastectomy with axillary lymph
node dissection (RR 2.52; 95% CI 1.25e5.11), and damaging of the intercostobrachial nerve (RR 2.05; 95% CI 1.25e3.37)
were predictors of a higher risk of NP. A total of 97 patients (62.2%, 95% CI 54.4e69.4) diagnosed with NP remained
symptomatic after six months.
Conclusion. NP and chronic NP were frequent in this population, being associated with anxiety and arm symptoms before
breast cancer treatments and type of surgical management. These results highlight the need for monitoring the occurrence of this
neurologic side effect of treatments and to develop strategies for reducing the morbidity burden of breast cancer. J Pain Symptom
Manage 2017;54:877e888.  2017 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
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Improvements in breast cancer survival,1 as a result
of earlier diagnosis and the use of more effective
treatments,2,3 as well as the overdiagnosis and over-
treatment associated with breast cancer screening,4
highlight the importance of morbidity, including
side effects of treatment, as contributors to the global
burden of breast cancer. Accordingly, in the most
developed countries, the years of life lived withAddress correspondence to: Nuno Lunet, PhD, Department of
Clinical Epidemiology, Predictive Medicine and Public
Health, Faculty of Medicine, University of Porto, Al. Prof.
 2017 American Academy of Hospice and Palliative Medicine.
Published by Elsevier Inc. All rights reserved.disability already correspond to approximately half
the number of years of life lost due to premature mor-
tality due to breast cancer.5
Neuropathic pain (NP), defined by the International
Association for the Study of Pain (IASP) as ‘‘pain
arising as a direct consequence of a lesion or disease
affecting the somatosensory system,’’6 can be an impor-
tant source of disability and distress in breast cancer pa-
tients already suffering from the psychological andHerna^ni Monteiro, 4200-319 Porto, Portugal. E-mail:
nlunet@med.up.pt
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ment and has been considered the most important
contributor to chronic breast pain.7 However, it is not
clear to what extent chronic postsurgical pain is neuro-
pathic in character. Previous studies that assessed the
frequency of NP among breast cancer patients yielded
prevalence estimates ranging between 8% and
26%:8e10 in a prospective study of women submitted
to surgery, Bruce et al.8 found a prevalence of 24% of
pain of predominantly NP origin at nine months, eval-
uated using the Self-Administered Leeds Assessment of
Neuropathic Symptoms and Signs (S-LANSS) and the
Neuropathic Pain Questionnaire (DN4); in a retro-
spective study including women treated for breast
cancer two to six years before, Bredal et al.9 reported
the occurrence of signs of NP in 26% of the partici-
pants, according to the S-LANSS; in a cross-
sectional study evaluating women after a mean time
of 9.5 years after diagnosis, 9% and 18% had NP,
when evaluated with the S-LANSS and the ID-Pain,
respectively.10 However, it was reported that NP
screening methods fail to identify 10e20% of pa-
tients with clinically diagnosed NP, and therefore, it
was suggested that despite they may offer guidance
for further diagnosis, they cannot replace clinical
evaluation.11,12 To standardize diagnostic criteria in
clinical and research, a grading system, to classify
the certainly with which the presence of NP can be
determined, was adopted by the IASP and by the Eu-
ropean Federation of Neurological Societies in their
guidelines on NP evaluation.11,12
A systematic review evaluating risk factors for the
development of persistent pain after surgery found
that, in addition to younger age, preoperative pain, in-
tercostobrachial nerve damage during surgery, and
radiotherapy, also psychological morbidities are among
the most frequently reported factors associated with
chronic pain after breast cancer treatment.13 In fact,
previous studies have reported an association between
anxiety and depression,8,14e17 and also quality of
sleep,14,16,17 and the occurrence of breast pain
following breast cancer treatment. However, there is
little information on the impact of these factors specif-
ically in NP. A recent systematic review addressed spe-
cifically determinants of persistent NP in high-quality
studies, defined based on previous published criteria
that evaluated risk of bias, and only included one study
that evaluated NP after breast cancer treatment.18
Notwithstanding, data on the relation between type
of surgery10,19,20 and radiotherapy10,19,21,22 and the
occurrence of NP remain conflicting across studies.
A prospective study with a systematic neurologic
evaluation of patients in different predetermined mo-
ments of the first year after breast cancer diagnosis,
including a baseline evaluation pre-treatment and a
clinical assessment of NP, may contribute for a betterunderstanding of this neurologic complication.
Therefore, we aimed to characterize and estimate
the incidence of NP in the first year after diagnosis
and to identify their main determinants.Methods
Study Design and Data Collection
We conducted a prospective cohort study of 506
women consecutively recruited in 2012 among those
with newly diagnosed breast cancer admitted to the
Breast Clinic of the Portuguese Institute of Oncology
of Porto, Portugal. The study methodology has been
described in detail elsewhere.23 Briefly, we consecu-
tively selected women proposed for surgery whose
follow-up would go on in the same hospital. We
excluded those previously treated for cancer, submit-
ted to breast surgery, and those scoring less than 17,
or less than 16 for women older than 65 years, in
the Montreal Cognitive Assessment, which was
assumed to correspond to a high probability of cogni-
tive impairment.24
All participants underwent neurologic evaluation,
and sociodemographic and medical data were
collected, at baseline (before any treatment), two
weeks after surgery, three weeks after chemotherapy
(if applicable), and at one year after the enrollment.
In addition to these evaluations, the patients diag-
nosed with NP during the first year of follow-up
were evaluated two more times: at the moment of
NP confirmation (which falls within the one-year
follow-up of the whole cohort) and six months after
(which may fall outside the one-year follow-up of the
whole cohort, depending on the timing of occur-
rence of NP). To define the chronicity of NP, a six-
month follow-up was considered; this period is
enough to ensure that patients had time to com-
plete chemotherapy and radiotherapy and is in
accordance with the recent Initiative on Methods,
Measurement, and Pain Assessment in Clinical Trials
(IMMPACT) recommendations for considering a
duration of at least three months to classify NP as
chronic.25
Incident cases of NP were identified through
referral by any member of the clinical team, or during
the systematic neurologic evaluations performed by
experienced neurologists. Cases identified at the
time of the scheduled follow-up evaluation were as-
signed an estimated date of onset based on informa-
tion provided by the patient.
Table 1 depicts the instruments, including the ques-
tionnaires validated for the Portuguese population,
used at baseline and follow-up evaluations. The evalu-
ations were performed by trained interviewers or
clinicians, as applicable. Medical data about breast
Table 1
Description of the Instruments for Evaluation of the Participants at Baseline and in the Different Moments of Follow-up,
Used for the Present Analysis
Instruments
Used for
Evaluation
Timing of Evaluation
Description of the Instrument
Baseline (Before
Breast Cancer
Treatment)
NP
Diagnosisa
6 Mo After NP
Diagnosisa
MoCA U Test for the rapid screening of mild cognitive impairmentdan intermediate
clinical state between normal cognitive aging and dementia (range
0e30).
HADS U Scale assessing anxiety and depression among patients during the previous
week (range for anxiety and depression: 0e21). Scores greater than five
indicate a case of anxiety and depression, respectively.
PSQI U Index assessing sleep quality during the previous month (range 0e21).
Scores greater than five indicate a case of sleep disturbance.
QLQ-BR23 U Scale assessing QoL in patients with breast cancer during the previous week
and month; two specific subscales were used to evaluate the existence of
breast and arm symptoms before treatments.
QLQ-C30 U Scale assessing QoL in patients with cancer during the previous week; the
median value of the global health status/QoL subscale was used to define
high and low global health status/QoL; the pain subscale was used to
define those with pain in the previous week.
BPI U Ub Questionnaire evaluating the severity and the impact of pain on the
patient’s daily function in the last 24 hours (range for intensity and
interference: 0e10); pain severity represents the mean of four items: pain
at its ‘‘worst,’’ ‘‘least,’’ ‘‘average,’’ and ‘‘current pain’’ (each of them
ranging between 0 and 10).
PDI U Ub Index assessing pain-related disability in seven different areas of life activity
(range of global score: 0e70); the median value was used as cutoff to
define lower and higher disability.
NP ¼ neuropathic pain; MoCA ¼ The Montreal Cognitive Assessment; HADS ¼ Hospital Anxiety and Depression Scale; PSQI ¼ Pittsburg Sleep Quality Index;
QLQ-BR23 ¼ Breast cancer-specific module of the Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer; QoL ¼
quality of life; QLQ-C30 ¼ Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer; BPI ¼ Brief Pain Inventory; PDI ¼
Pain Disability Index.
aApplicable only when incident NP was diagnosed in the first years of follow-up.
bApplicable only when NP is present at the moment of evaluation.
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clinical records and revised by a surgeon with experi-
ence in breast cancer surgery.
The classification system proposed by the IASP was
used to classify NP;12 NP was considered probable if
pain had a distinct neuroanatomically plausible distri-
bution and history was suggestive of relevant lesion or
disease affecting the peripheral or central somatosen-
sory system, plus negative or positive sensory signs in
neurologic examination, confined to the innervation
territory of the injured nervous structure. NP was
considered chronic when still present six months after
its diagnosis, in the same localization, and still fulfill-
ing the IASP criteria to probable NP diagnosis, after
clinical examination. Pain sensation (pin prick) was
assessed with a wood cocktail-stick and light touch
sensation (brush) by a piece of cotton wool, as recom-
mended by the IASP.12
The pharmacologic management of NP was assessed
through patients’ self-report and data collected from
clinical files. For each drug, data were collected on
the maximum daily dose and duration of the treat-
ment; only drugs prescribed for continued use were
considered in data analysis.Statistical Analysis
We computed cumulative incidence estimates for
NP at the one-year follow-up and the corresponding
95% CIs. Kaplan-Meier failure estimates were
plotted to describe the incidence over the follow-
up period.
Crude and adjusted cumulative incidence ratios
(RRs) and corresponding 95% CI for the relation be-
tween different characteristics of the patients and the
occurrence of NP and NP with severity $3 in the first
year after enrollment, or chronic NP and chronic NP
with severity $3 at six months after it was first
observed, were computed using Poisson regression;
the variables included in each model are described
in footnotes in each table with these results. Pain
severity, pain interference, and pain-related disability,
at the moment of NP diagnosis and after six-months
of follow-up, were described according to pharmaco-
logic treatment for NP.
Training of the interviewers and use of standardized
procedures for data collection contributed to a low
proportion of missing data, and no imputation was
done. Statistical analysis was conducted using STATA,
version 11.2 (StataCorp, College Station, TX).
Table 2
Demographic and Medical Characteristics of the Breast
Cancer Patients (N ¼ 506)
Characteristics n (%)a
Age, yrs (median [P25eP75]) 54.9 (47.2e63.4)
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The study was approved by the Ethics Committee of
the Portuguese Institute of Oncology of Porto (CES
406/011) and all patients provided written informed
consent.Education, yrs (median [P25eP75]) 6 (4e11)
Age, yrs
<50 178 (35.2)
$50 328 (64.8)
Education, yrsb
#4 216 (42.7)
5e9 146 (28.9)
$10 144 (28.5)
Retired 125 (24.7)
Cancer stage at baselineb
0c 35 (6.9)
I 236 (46.6)
II 156 (30.8)
III 75 (14.8)
IV 4 (0.8)
Breast cancer laterality
Left 257 (50.8)
Right 240 (47.4)
Bilateral 9 (1.8)
Breast surgeryd
Mastectomy 254 (50.3)
Breast-conserving 250 (49.5)
Axillary surgerye
ALND 174 (34.5)
SLNB 316 (62.6)
Intercostobrachial nerve status
Preserved 326 (64.6)
Damaged 141 (27.9)
Without information 38 (7.5)
Neoadjuvant therapy
Chemotherapy 35 (6.9)
Adjuvant therapyf
Chemotherapy 265 (52.5)
Radiotherapyg 367 (73.0)
Brachytherapyg 95 (18.9)
Endocrine therapyg 422 (83.9)
Immunotherapyg 68 (13.5)
P25eP75 ¼ percentile 25epercentile 75; ALND ¼ axillary lymph node dissec-
tion; SLNB ¼ sentinel lymph node biopsy.
aResults are preset as n (%), except if otherwise specified; data regarding
treatment are not available for one patient who abandoned the study before
the post-surgery evaluation.
bDoes not sum 100.0% due to rounding.
cStage 0 breast cancer corresponds to cases of ductal carcinoma in situ; the
cancer stage of one patient is based on clinical information because she aban-
doned the study before the post-surgery evaluation.
dThose patients who had both mastectomy and breast-conserving surgery are
reported as mastectomy; does not sum 100.0% because one patient only per-
formed axillary surgery.
ePatients who had both ALND and SLNB are reported as ALND; does not sum
100.0% because 15 patients only performed breast surgery.
fDoes not sum 100.0% because patients could be submitted to more than one
type of treatment.
gData are only available for the 503 patients who completed the one-year
follow-up evaluation.Results
A total of 503 participants (99.4%) completed the
one-year follow-up evaluation; one patient died and
two patients abandoned the study (no reason
specified). The mean (SD) of follow-up was 379.0
(28.6) days.
Patients’ Characteristics
The main demographic and medical characteristics
of the participants are presented in Table 2. At base-
line, 35.2% of the women were younger than 50 years,
71.6% had up to nine years of education, and 24.7%
were retired. A total of 53.5% were diagnosed ductal
carcinoma in situ or Stage I breast cancer, 50.3%
were submitted to mastectomy, 34.5% underwent axil-
lary lymph node dissection (ALND), and for 27.9%
intercostobrachial nerve damage during the surgical
procedure was reported. Most patients went on to
adjuvant treatmentdendocrine therapy, radiotherapy,
or chemotherapy.
Incidence and Characterization of Neuropathic Pain
During the First Year of Follow-up
During the first year after diagnosis, 156 patients
were diagnosed with NP (30.8%, 95% CI 27.0e35.0).
All cases had clinical diagnosis and were classified as
probable, according to the criteria proposed by the
IASP.12
The clinical characteristics of NP are presented in
Table 3. The symptoms onset was after surgery in
71.8% of the patients. NP was localized in the arm,
thoracic/breast region, and axillary region in 67.9%,
48.7%, and 45.5% of the women, respectively, and
3.2% of the patients reported symptoms in hands/
feet; the latter correspond to patients also diagnosed
with chemotherapy-induced peripheral neuropathy.
All patients reported at least one positive neuropathic
sensory symptom (pins and needles, tingling, electric
shocks, or burning); 81.4% reported the presence at
least of two. On neurologic examination, allodynia
(pain induced by a non-nociceptive stimulus) was
reported by 87.0% of the patients.
The median scores (range; percentile 25e
percentile 75 [P25-P75]) in the moment of NP diag-
nosis were 2.5 (0.5e9.0; 1.5e3.8) for pain severity, 4
(1.0e10.0; 3.0e5.0) for the for worse pain intensity
in last 24 hours, 2 (0.0e10.0; 0.0e4.0) for current
pain intensity, 1.8 (0e9.4; 0.9e3.6) for paininterference, and 15 (0.0e70.0; 7.0e29.0) for pain-
related disability.
Predictors of Neuropathic Pain During the First Year
of Follow-up
Table 4 presents RR for the relation between
different characteristics of the patients and the occur-
rence of NP in surgical areas during the first year after
Table 3
Clinical Characteristics of Neuropathic Pain (n ¼ 156)
Characteristics n (%)
Timing of pain onset
After neoadjuvant chemotherapy 3 (1.9)a
After surgery 112 (71.8)
After adjuvant chemotherapy 9 (5.8)b
After radiotherapy 32 (20.5)c
Location of paind
Arm 106 (67.9)
Thoracic/breast region 76 (48.7)
Axillary region 71 (45.5)
Hands/feet 5 (3.2)
Pain characteristics
Burning sensation 83 (53.2)
Painful cold sensation 63 (40.4)
Electric shocks sensation 67 (42.9)
Tingling sensation 84 (53.8)
Pins and Needles sensation 143 (91.7)
Numbness sensation 151 (96.8)
Itching sensation 70 (44.9)
Hypoesthesia to touch 152 (97.4)
Hypoesthesia to prick 151 (96.8)
Allodynia 87 (55.8)
Mechanical allodynia 87 (55.8)
Static mechanical allodynia 81 (51.9)
Dynamic mechanical allodynia 34 (21.8)
Thermal allodynia 12 (7.7)
Thermal allodynia to a cold stimulus 10 (6.4)
Thermal allodynia to a hot stimulus 5 (3.2)
a20 Patients diagnosed with neuropathic pain performed neoadjuvant
chemotherapy.
b93 Patients diagnosed with neuropathic pain performed adjuvant
chemotherapy.
c115 Patients diagnosed with neuropathic pain performed radiotherapy.
dDoes not sum 100.0% because patients may have pain in more than one
location.
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risk and those with anxiety, arm symptoms before
treatments, submitted to breast-conserving surgery
with ALND or mastectomy with ALND, were at greater
risk of NP, regardless of its severity at diagnosis. Addi-
tionally, cancer Stage III/IV, pain at baseline, and
damaging of the intercostobrachial nerve were related
with higher risk of NP, although results were not statis-
tically significant when only the cases of NP with
severity score $3 were considered. When further
adjusted for breast and arm symptoms at baseline,
pain at baseline was no longer a predictor of NP
(RR 1.28, 95% CI 0.88e1.87).
From the 316 patients who underwent sentinel
lymph node biopsy (SLNB) without ALND, we found
NP in intercostobrachial nerve territory in 35 (11.1%).
Figure 1 depicts the cumulative incidence of NP in
the surgical area during follow-up by breast and axil-
lary surgery. Patients undergoing breast-conserving
surgery and SLNB had a lower risk throughout the
follow-up. Patients submitted to ALND had a higher
risk of developing NP one month after the procedure
than those undergoing mastectomy with SLNB, and
the difference became more pronounced after six
months of follow-up.Neuropathic Pain During the Six-Month Follow-up
After Its Diagnosis
The mean (SD) follow-up of the subcohort of NP
patients was 190.5 (24.0) days. During this period,
37.2% of the patients diagnosed with NP received
pharmacologic treatment for NP; the most frequent
prescriptions were gabapentin (82.8%, maximum
daily dose range 200e2400 mg) and pregabalin
(31.0%, maximum daily dose range: 150e600 mg).
Three patients with intercostobrachial neuralgia
were referred to pain consultation for nerve block.
At the end of follow-up, 27.6% of patients who had
been pharmacologically treated for NP were no longer
under treatment; among these, the median (P25-P75)
duration of treatment was 58 (30e138) days.
A total of 97 (62.2%, 95% CI 54.4e69.4) of all pa-
tients diagnosed with NP remained symptomatic for
at least six months after the diagnosis. A total of 30
(30.9%, 95% CI 22.6e40.7) had NP with severity score
$3 and 12 (12.4%, 95% CI 7.1e20.5) had NP with
severity score $4. The median scores (range;
P25-P75) for the worse pain intensity in last 24 hours
and current pain intensity were 4 (1.0e9.0; 2.0e5.0)
and 1 (0.0e8.0; 0.0e3.0), respectively.
As depicted in Figure 2, there was a decrease in the
median scores for pain severity, pain interference, and
pain-related disability, between the diagnosis of NP and
the six-month follow-up among patients not submitted
to pharmacologic treatment (from 2.0 to 0.4
[P < 0.001], from 1.1 to 0.0 [P < 0.001], and from 10
to 0 [P < 0.001], respectively). Among the patients
treated pharmacologically for NP, there was also a reduc-
tion in the three scores from 3.8 to 2.1 (P< 0.001), from
4.3 to 1.9 (P< 0.001), and from 31.0 to 14.5 (P< 0.001).
Nevertheless, among the latter the scores were higher
both at diagnosis and at follow-up.
Table 5 presents RR for the relation between
different characteristics of the patients and chronic
NP among patients with incident NP. In the multivari-
able analysis, only pharmacologic treatment for NP
was significantly associated with chronic NP with
severity score $3.
From the 35 patients who underwent SLNB without
ALND and were diagnosed NP in intercostobrachial
nerve territory, 10 (28.6%) maintained the pain in
that location at the end of follow-up (3.2% from all
submitted to SLNB without ALND), and seven of
those (70.0%) had NP with severity score $3.Discussion
The present study provides a comprehensive assess-
ment of the incident NP and chronic NP in the first
year after breast cancer diagnosis and treatment. It
has several distinctive methodologic features that
Table 4
Crude and Adjusted RR and Corresponding 95% CI for the Relation Between Different Characteristics of the Patients and the Occurrence of Neuropathic Pain or
Neuropathic Pain With Severity Score $3a in the First Year After Enrollment (N ¼ 506)
Characteristics Patients With NP, n (%) Adjusted RR (95% CI) Patients With NP With Severity $3, n (%) Adjusted RR (95% CI)
Age (yrs)
<50 67 (37.6) 1 (ref.) 34 (19.1) 1 (ref.)
$50 84 (25.6) 0.68 (0.49e0.94) 33 (10.1) 0.53 (0.33e0.85)
Education (yrs)
#4 56 (25.9) 1 (ref.) 24 (11.1) 1 (ref.)
5e9 50 (34.2) 1.16 (0.78e1.74)b 22 (15.1) 1.07 (0.58e1.98)b
$10 45 (31.2) 1.07 (0.71e1.61)b 21 (14.6) 1.05 (0.57e1.95)b
Anxiety at baseline (HADS) (n ¼ 505c)
No 73 (23.3) 1 (ref.) 27 (8.6) 1 (ref.)
Yes 78 (40.6) 1.50 (1.06e2.13)d 40 (20.8) 2.14 (1.26e3.63)d
Depression at baseline (HADS)
No 131 (28.2) 1 (ref.) 58 (12.5) 1 (ref.)
Yes 20 (48.8) 1.21 (0.73e1.99)d 9 (21.9) 1.08 (0.51e2.27)d
Sleep disturbance at baseline (PSQI) (n ¼ 505c)
No 52 (25.9) 1 (ref.) 18 (9.0) 1 (ref.)
Yes 99 (32.6) 0.98 (0.68e1.40)d 49 (16.1) 1.45 (0.82e2.57)d
Global health status/QoL at baseline (QLQ-C30)
High 67 (24.8) 1 (ref.) 36 (13.3) 1 (ref.)
Low 84 (35.6) 1.21 (0.86e1.71)d 31 (13.1) 0.70 (0.42e1.17)d
General pain at baseline (QLQ-C30)
No 57 (23.1) 1 (ref.) 24 (9.7) 1 (ref.)
Yes 94 (36.3) 1.43 (1.01e2.01)e 43 (16.6) 1.61 (0.95e2.72)e
Breast symptoms at baseline (QLQ-BR23)
No 47 (22.5) 1 (ref.) 19 (9.1) 1 (ref.)
Yes 104 (35.0) 1.15 (0.79e1.66)d 48 (16.2) 1.18 (0.67e2.08)d
Arm symptoms at baseline (QLQ-BR23)
No 61 (22.7) 1 (ref.) 24 (8.9) 1 (ref.)
Yes 90 (38.0) 1.44 (1.02e2.05)d 43 (18.1) 1.80 (1.06e3.07)d
Cancer stagef
0/I 59 (21.8) 1 (ref.) 26 (9.6) 1 (ref.)
II 47 (30.1) 1.32 (0.89e1.94)g 25 (16.0) 1.53 (0.87e2.66)g
III/IV 45 (57.0) 2.47 (1.66e3.66)g 16 (20.2) 1.89 (1.00e3.56)g
Number of surgeries
1 130 (30.2) 1 (ref.) 56 (13.0) 1 (ref.)
$2 21 (28.4) 0.89 (0.55e1.44)h 11 (14.9) 0.92 (0.47e1.83)h
Surgeryi (n ¼ 487)
BC þ SLNB 31 (16.4) 1 (ref.) 10 (5.3) 1 (ref.)
M þ SLNB 34 (26.8) 1.27 (0.58e2.77)h 19 (15.0) 1.40 (0.44e4.39)h
BC þ ALND 22 (46.8) 3.13 (1.51e6.48)h 8 (17.0) 3.45 (1.10e10.86)h
M þ ALND 63 (50.0) 2.53 (1.25e5.11)h 30 (23.8) 3.24 (1.23e9.29)h
Intercostobrachial nerve status (n ¼ 467c)
Preserved 66 (20.3) 1 (ref.) 28 (8.6) 1 (ref.)
Damaged 68 (48.2) 2.05 (1.25e3.37)j 30 (21.3) 2.01 (0.98e4.11)j
Chemotherapy (Adjuvant þ neoadjuvant)
No 43 (21.0) 1 (ref.) 18 (8.8) 1 (ref.)
Yes 108 (36.0) 1.18 (0.74e1.89)h,g 49 (16.3) 1.39 (0.69e2.81)h
Radiotherapyk
No 40 (28.8) 1 (ref.) 24 (17.7) 1 (ref.)
Yes 111 (30.2) 0.84 (0.43e1.62)h 43 (11.7) 0.54 (0.22e1.34)h
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Fig. 1. Kaplan-Meier failure estimates to describe the inci-
dence of neuropathic pain over the follow-up period, by
breast and axillary surgery (n ¼ 484 [data are not depicted
for 15 patients who only performed breast surgery [breast
conserving], one patient who only performed axillary sur-
gery [ALND], and for the five patients with pain in
hands/feet.]). ALND ¼ axillary lymph node dissection;
SLNB ¼ sentinel lymph node biopsy.
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rence of this neurologic complication of cancer treat-
ment, and to our knowledge, this is the first
investigation providing this type of clinical data in
Portugal. Our study adds to previous research on
this topic the standardized prospective assessment of
NP, using the most recent diagnostic criteria recom-
mended by the IASP and the recent IMMPACT recom-
mendations to classify NP as chronic.25 Most previous
studies evaluated pain in general, not describing spe-
cifically NP, or assessing NP using screening tools,
such as the DN4 and the S-LANSS. However, only
the examination of somatosensory functions provide
supporting evidence for altered function of the ner-
vous system and can address the issue of presence of
other types of pathologic processes that cause pain,
like inflammation or edema.12 Another important
methodologic strength is the nearly complete follow-
up of the main cohort and a complete follow-up of
the subcohort of NP patients.
Previous studies addressed the frequency of NP in
breast cancer patients: a retrospective study conducted
in Norway reported the presence of pain in 41% of the
participants, from whom approximately one-third re-
ported symptoms and signs of NP, according to the
S-LANSS;9 from Scotland, a prospective cohort study
found an incidence of predominantly NP of 26%
and 24% at four and nine months, respectively, ac-
cording to S-LANSS or DN4;8 from the U.S., a cross-
sectional study reported prevalences of NP ranging
from 9% to 18%, when evaluated with the S-LANSS
and the ID-Pain, respectively. Despite the use of
different methods and criteria to define NP or chronic
NP, our study yielded similar estimates of the fre-
quency of NPdnearly one-third of the women were
Fig. 2. Characterization of neuropathic pain, concerning pain severity, pain interference, and pain-related disability, at the
moment of pain diagnosis and after six months of follow-up, according to pharmacologic treatment for neuropathic pain
(n ¼ 156); P-values computed using paired Student t-test. NP ¼ neuropathic pain.
884 Vol. 54 No. 6 December 2017Pereira et al.diagnosed with NP, from whom approximately two-
thirds remained with NP six months after the
diagnosis.
Despite previous studies evaluated predictors of
chronic pain in breast cancer,8,9,13 to our knowledge,
this is the first addressing specifically NP, which pre-
cludes direct comparisons. Nevertheless, the fact that
younger age, anxiety, arm symptoms, cancer stage
III/IV, intercostobrachial nerve damage, and ALND
were predictors of higher risk of NP is in accordance
with previous observations for pain in general, and
further supports the hypothesis that NP has an impor-
tant share in the overall frequency of pain. However, it
is noteworthy that only part of the patients with NP
had a severity score $3, which is expectedly a more
clinically relevant outcome. In addition to younger
age, arm symptoms, and ALND, the presence of anxi-
ety remained associated with NP when only the cases
with greater severity were considered. The association
between anxiety levels before cancer treatment and
the occurrence of pain after breast cancer surgery
was previously reported in other longitudinal
studies,8,26,27 although its relation remains poorlyunderstood. We may hypothesize that anxious patients
have lower tolerance to pain by decrease of pain
threshold and, therefore, reported its occurrence
more frequently.
Our study also differs from the previous ones by dis-
entangling the determinants of NP and evolution for
chronic NP; among women with an NP diagnosis,
chronic NP was not significantly associated with any
of the previous variables, although higher severity or
interference with daily activities yielded the strongest
associations, and lack of statistical significance may
reflect lack of statistical power for the assessment of
chronic NP determinants among those with NP. Phar-
macologic treatment for NP was associated with an
increased risk of chronic NP with severity score $3,
which is likely to reflect mostly indication bias that
could not be overcome by multivariable analysis. In
this respect, gabapentin and pregabalin were the
most frequently used drugs to treat NP, in line with
the recommendations for the pharmacologic manage-
ment of this condition.28,29 Contrary to previous find-
ings regarding chronic pain in general,9 in our study,
the frequency of chronic pain was not increased among
Table 5
Crude and Adjusted Relative Risks for the Relation Between Different Characteristics of the Patients and Chronic NP and Chronic NP With Severity $3a at 6 Months
After It Was First Observed (n ¼ 151)
Characteristics Patients With Chronic NP, n (%) Adjusted RR (95% CI)
Patients With Chronic NP With
Severity $3, n (%) Adjusted RR (95% CI)
Age (yrs)
<50 43 (64.2) 1 (ref.) 18 (26.9) 1 (ref.)
$50 52 (61.9) 0.96 (0.64e1.44) 11 (13.0) 0.49 (0.23e1.03)
Education (yrs)
#4 35 (62.5) 1 (ref.) 8 (14.2) 1 (ref.)
5e9 30 (60.0) 0.94 (0.56e1.59)b 10 (20.0) 1.06 (0.39e2.86)b
$10 30 (66.7) 1.05 (0.63e1.76)b 11 (24.4) 1.31 (0.50e3.46)b
Anxiety at baseline (HADS)
No 41 (56.2) 1 (ref.) 9 (12.3) 1 (ref.)
Yes 54 (69.2) 1.17 (0.75e1.82)c 20 (25.6) 2.00 (0.87e4.62)c
Depression at baseline (HADS)
No 82 (62.6) 1 (ref.) 25 (19.1) 1 (ref.)
Yes 13 (65.0) 0.90 (0.48e1.70)c 4 (20.0) 0.87 (0.28e2.70)c
Sleep disturbance at baseline (PSQI)
No 27 (51.9) 1 (ref.) 6 (11.5) 1 (ref.)
Yes 68 (68.7) 1.24 (0.79e1.96)c 23 (23.3) 1.74 (0.69e4.34)c
Global health status/QoL at baseline (QLQ-C30)
High 41 (61.2) 1 (ref.) 15 (22.4) 1 (ref.)
Low 54 (64.3) 0.99 (0.65e1.52)c 14 (16.7) 0.73 (0.34e1.59)c
General pain at baseline (QLQ-C30)
No 29 (50.9) 1 (ref.) 9 (15.8) 1 (ref.)
Yes 66 (70.2) 1.33 (0.84e2.10)d 20 (21.3) 1.23 (0.54e2.80)d
Breast symptoms at baseline (QLQ-BR23)
No 24 (51.1) 1 (ref.) 6 (12.8) 1 (ref.)
Yes 71 (68.3) 1.17 (0.71e1.92)c 23 (22.1) 1.13 (0.43e2.95)c
Arm symptoms at baseline (QLQ-BR23)
No 31 (50.8) 1 (ref.) 9 (14.8) 1 (ref.)
Yes 64 (71.1) 1.35 (0.84e2.17)c 20 (22.2) 1.71 (0.72e4.09)c
Pain severity at NP diagnosis (BPI) (n ¼ 147e)
Lower level 41 (52.6) 1 (ref.) 5 (6.4) 1 (ref.)
Higher level 52 (75.4) 1.31 (0.79e2.17)f 24 (34.8) 2.49 (0.82e7.58)f
Pain interference at NP diagnosis (BPI)
Lower level 41 (55.4) 1 (ref.) 3 (4.0) 1 (ref.)
Higher level 54 (70.1) 1.12 (0.62e2.04)f 26 (33.8) 4.50 (0.97e20.81)f
Pain-related disability at NP diagnosis (PDI)
Lower level 41 (56.2) 1 (ref.) 4 (5.5) 1 (ref.)
Higher level 51 (68.9) 1.00 (0.54e1.87)f 25 (33.8) 1.28 (0.30e5.43)f
Pharmacologic treatment for NP
No 48 (51.1) 1 (ref.) 4 (4.3) 1 (ref.)
Yes 47 (82.5) 1.61 (0.90e2.87)g 25 (43.9) 4.40 (1.17e16.61)g
Cancer stageh
0/I 37 (62.7) 1 (ref.) 8 (13.6) 1 (ref.)
II 30 (63.8) 1.01 (0.62e1.67)i 12 (25.5) 1.59 (0.63e4.01)i
III/IV 28 (62.2) 0.98 (0.59e1.64)i 9 (20.0) 1.21 (0.45e3.25)i
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Continued
Characteristics Patients With Chronic NP, n (%) Adjusted RR (95% CI)
Patients With Chronic NP With
Severity $3, n (%) Adjusted RR (95% CI)
Number of surgeries
1 82 (63.1) 1 (ref.) 25 (19.2) 1 (ref.)
$2 13 (61.9) 1.00 (0.53e1.91)j 4 (19.0) 1.26 (0.38e4.16)j
Surgeryk (n ¼ 150)
BC þ SLNB 18 (58.1) 1 (ref.) 4 (12.9) 1 (ref.)
M þ SLNB 24 (70.6) 1.21 (0.47e3.10)j 8 (23.5) 1.21 (0.18e8.26)j
BC þ ALND 14 (63.6) 0.94 (0.36e2.44)j 6 (27.3) 0.73 (0.16e3.45)j
M þ ALND 38 (60.3) 0.94 (0.39e2.25)j 11 (17.5) 0.71 (0.15e3.34)j
Intercostobrachial nerve status (n ¼ 134e)
Preserved 40 (60.6) 1 (ref.) 10 (15.2) 1 (ref.)
Damaged 43 (63.2) 1.06 (0.54e2.07)l 16 (23.5) 1.41 (0.47e4.26)l
Chemotherapy (Adjuvant þ neoadjuvant)
No 27 (62.8) 1 (ref.) 4 (9.3) 1 (ref.)
Yes 68 (63.0) 1.06 (0.58e1.94)j 25 (23.2) 2.43 (0.66e8.89)j
Radiotherapy
No 27 (67.5) 1 (ref.) 9 (22.5) 1 (ref.)
Yes 68 (61.3) 0.96 (0.43e2.16)j 20 (18.0) 0.51 (0.10e2.50)j
Brachytherapy
No 85 (62.5) 1 (ref.) 24 (17.6) 1 (ref.)
Yes 10 (66.7) 1.15 (0.53e2.51)j 5 (33.3) 2.33 (0.63e8.67)j
Endocrine therapy
No 16 (64.0) 1 (ref.) 5 (20.0) 1 (ref.)
Yes 79 (62.7) 1.03 (0.58e1.82)j 24 (19.0) 1.04 (0.38e2.82)j
Immunotherapy
No 83 (62.9) 1 (ref.) 25 (18.9) 1 (ref.)
Yes 12 (63.2) 1.00 (0.53e1.91)j 4 (21.0) 0.96 (0.32e2.93)j
NP ¼ neuropathic pain; RR ¼ relative risk; HADS ¼ Hospital Anxiety and Depression Scale; PSQI ¼ Pittsburg Sleep Quality Index; QoL ¼ quality of life (the median value was used to define high and low quality of life:
between 16.6 and 58.4 and between 58.5 and 100, respectively); QLQ-C30 ¼ Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer; QLQ-BR23 ¼ breast cancer-specific
module of the Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer; BPI ¼ Brief Pain Inventory (the median value was used to define lower and higher level of pain severity
[between 0.0 and 2.5 and between 2.6 and 10, respectively] and pain interference [between 0.00 and 1.79 and between 1.78 and 10, respectively]); PDI ¼ Pain Disability Index (the median value was used to define lower
and higher level of pain-related disability [between 0 and 15 and between 16 and 70, respectively]); BC ¼ breast conserving; SLNB ¼ sentinel lymph node biopsy; M ¼mastectomy; ALND ¼ axillary lymph node dissection.
aThe outcomes were defined as chronic NP (n ¼ 95) and chronic NP with severity score $3 (n ¼ 29) in surgical area, respectively.
bAdjusted for age.
cAdjusted for age, education, anxiety, depression, sleep quality, global health status, breast symptoms, arm symptoms and breast cancer stage, as applicable.
dAdjusted for age, education, anxiety, depression, sleep quality, global health status, and breast cancer stage.
en < 151 due to missing data.
fAdjusted for age, education, anxiety, depression, sleep quality, global health status, breast symptoms, arm symptoms, pain severity, pain interference, pain-related disability, breast cancer stage, number of surgeries, and
type of surgery, as applicable.
gAdjusted for age, education, pain severity, pain interference, pain-related disability, and cancer stage.
hStage 0 breast cancer corresponds to cases of ductal carcinoma in situ.
iAdjusted for age and education.
jAdjusted for age, breast cancer stage, number of surgeries, type of surgery, chemotherapy, radiotherapy, brachytherapy, endocrine therapy, and immunotherapy, as applicable.
kThose patients who had both mastectomy and breast-conserving surgery are reported as mastectomy and those who had ALND and SLNB are reported as ALND.
lAdjusted for age, breast cancer stage, number of surgeries, breast surgery, chemotherapy, radiotherapy, brachytherapy, endocrine therapy, and immunotherapy.
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Vol. 54 No. 6 December 2017 887Neuropathic Pain After Cancer Treatmentsubjects with pain previous to treatments, although this
was evaluated with a subscale of QLQ-C30 that assesses
pain and disability in daily functions related to pain.
We observed only five cases of NP in patients with
chemotherapy-induced neuropathy, which probably re-
flects the fact that at thePortuguese Institute ofOncology
of Porto docetaxel is used more often in incident breast
cancer than paclitaxel, which is more neurotoxic.30
It has been described that in just over 10% of the
cases the axillary sentinel lymph node intercostobra-
chial nerve territory is located above the second inter-
costobrachial nerve and can be damaged at that
localization during biopsy in approximately 5.3% of
SLNB.31 This is consistent with our observations that
3.2% of the patients underwent SLNB without
ALND, had chronic NP, but highlights the problem
of sequelae secondary to overdiagnosis and overtreat-
ment of breast cancer.32
Despite the contribution of the present study for an
accurate characterization of NP among breast cancer
patients at early stages, some limitations need to be ad-
dressed, especially regarding the external validity of
the results. We evaluated essentially women with early
breast cancer, which limits the generalization to pa-
tients with more advanced disease. Although all pa-
tients were selected and treated in the same
institution, the Portuguese Institute of Oncology of
Porto is the largest hospital providing care to onco-
logic patients in the north of Portugal, which receives
patients referred from a wide geographical area.
In conclusion, NP and chronic NP were frequent in
the first year after incident breast cancer diagnosis, be-
ing associated with anxiety and arm symptoms before
breast cancer treatments, as well as factors related with
the type of surgical management. These results highlight
the need for monitoring the occurrence of this neuro-
logic side effect of treatments and to develop strategies
for reducing the morbidity burden of breast cancer.Disclosures and Acknowledgments
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